

U.S. Peptide Therapeutics (Retail Side) Market Size, Share & Trends Analysis Report By Peptide Type, By Indication, By Route of Administration, By Therapeutics Type, By Distribution Channel, And Segment Forecasts, 2025 - 2033

<https://marketpublishers.com/r/U117542447E1EN.html>

Date: August 2025

Pages: 165

Price: US\$ 3,950.00 (Single User License)

ID: U117542447E1EN

Abstracts

U.S. Peptide Therapeutics (Retail Side) Market Summary

The U.S. peptide therapeutics (retail side) market size was estimated at USD 103.66 billion in 2024 and is expected to reach USD 336.12 billion by 2033, growing at a CAGR of 12.77% from 2025 to 2033. The increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, highlights the need for affordable and effective treatment options. In addition, the increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, underscores the need for affordable and effective treatment options.

U.S. Peptide Therapeutics (Retail Side) Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. peptide therapeutics (retail side) market report based on peptide type, therapeutics type, indication, route of administration, and distribution channel:

Peptide Type Outlook (Revenue, USD Billion, 2021 - 2033)

GLP-1 Peptides

Wellness/Longevity/Healthspan Peptides

Peptides for Other Acute or Chronic Medical Conditions

Therapeutics Type Outlook (Revenue, USD Billion, 2021 - 2033)

Innovative (Branded) Peptides

Biosimilar Peptides

Generic Peptides

Indication Outlook (Revenue, USD Billion, 2021 - 2033)

Type 2 Diabetes

Obesity / Weight Management

Neuroendocrine Tumors

Acromegaly

Growth Hormone Deficiency

Prostate Cancer

Osteoporosis

Breast Cancer (hormone-sensitive)

Endometriosis

Others

Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)

Parenteral

Oral

Transdermal

Nasal

Others

Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

Offline Retail Pharmacies

Chain pharmacies

Specialty retail pharmacies

Independent community pharmacies

Online Pharmacies / Telehealth

Others (Specialized Peptide Clinics)

This report can be delivered to the clients within 3 Business Days

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
 - 1.1.1. Segment Definitions
- 1.2. Estimates and Forecast Timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased Database
 - 1.4.2. GVR's Internal Database
 - 1.4.3. Secondary Sources
 - 1.4.4. Primary Research
 - 1.4.5. Details of Primary Research
 - 1.4.6. Research Assumption
- 1.5. Information or Data Analysis
 - 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Data Visualization
- 1.7. Model Details
 - 1.7.1. Commodity Flow Analysis
- 1.8. Objectives
 - 1.8.1. Objective - 1
 - 1.8.2. Objective - 2
 - 1.8.3. Objective - 3
- 1.9. List of Secondary Sources
- 1.10. List of Secondary Sources

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. U.S. Peptide Therapeutics (Retail Side) Market
 - 2.1.1. Market Snapshot
 - 2.1.2. Segment Snapshot
 - 2.1.2.1. Therapeutics type & indication segment outlook
 - 2.1.2.2. Route of administration & distribution channel segment outlook
 - 2.1.3. Competitive Landscape Snapshot

CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook

- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
 - 3.3.1. Market Driver Analysis
 - 3.3.2. Market Restraint Analysis
- 3.4. Regulatory Framework
- 3.5. Business Environment Analysis Tools
 - 3.5.1. Industry Analysis - Porter's Five Forces Analysis
 - 3.5.1.1. Supplier power
 - 3.5.1.2. Buyer power
 - 3.5.1.3. Substitution threat
 - 3.5.1.4. Threat of new entrant
 - 3.5.1.5. Competitive rivalry
 - 3.5.2. PESTEL Analysis
- 3.6. Pricing Analysis in Online vs. Offline Channels
- 3.7. Consumer Awareness Trends for Peptide Therapies
- 3.8. Direct-to-Consumer (DTC) Business Models Impact

CHAPTER 4. PEPTIDE TYPE BUSINESS ANALYSIS

- 4.1. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Movement Analysis
- 4.2. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Segment Dashboard
- 4.3. Peptide Type Movement & Market Share Analysis, 2024 & 2033
- 4.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Peptide Type
- 4.5. GLP-1 Peptides
 - 4.5.1. GLP-1 Peptides Market, 2021 - 2033 (USD Million)
- 4.6. Wellness/Longevity/Healthspan Peptides
 - 4.6.1. Wellness/Longevity/Healthspan Peptides Market, 2021 - 2033 (USD Million)
- 4.7. Peptides for Other Acute or Chronic Medical Conditions
 - 4.7.1. Peptides for Other Acute or Chronic Medical Conditions Market, 2021 - 2033 (USD Million)

CHAPTER 5. THERAPEUTICS TYPE BUSINESS ANALYSIS

- 5.1. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Movement Analysis
- 5.2. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Segment

Dashboard

5.3. Therapeutics Type Movement & Market Share Analysis, 2024 & 2033

5.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Therapeutics Type

5.5. Innovative (Branded) Peptides

5.5.1. Innovative (Branded) Peptides Market, 2021 - 2033 (USD Million)

5.6. Biosimilar Peptides

5.6.1. Biosimilar Peptides Market, 2021 - 2033 (USD Million)

5.7. Generic Peptides

5.7.1. Generic Peptides Market, 2021 - 2033 (USD Million)

CHAPTER 6. INDICATION BUSINESS ANALYSIS

6.1. U.S. Peptide Therapeutics (Retail Side) Market: Indication Movement Analysis

6.2. U.S. Peptide Therapeutics (Retail Side) Market: Indication Segment Dashboard

6.3. Indication Movement & Market Share Analysis, 2024 & 2033

6.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Indication

6.5. Type 2 Diabetes

6.5.1. Type 2 Diabetes Market, 2021 - 2033 (USD Million)

6.6. Obesity / Weight Management

6.6.1. Obesity / Weight Management Market, 2021 - 2033 (USD Million)

6.7. Neuroendocrine Tumors

6.7.1. Neuroendocrine Tumors Market, 2021 - 2033 (USD Million)

6.8. Acromegaly

6.8.1. Acromegaly Market, 2021 - 2033 (USD Million)

6.9. Growth Hormone Deficiency

6.9.1. Growth Hormone Deficiency Market, 2021 - 2033 (USD Million)

6.10. Prostate Cancer

6.10.1. Prostate Cancer Market, 2021 - 2033 (USD Million)

6.11. Osteoporosis

6.11.1. Osteoporosis Market, 2021 - 2033 (USD Million)

6.12. Breast Cancer (hormone-sensitive)

6.12.1. Breast Cancer (hormone-sensitive) Market, 2021 - 2033 (USD Million)

6.13. Endometriosis

6.13.1. Endometriosis Market, 2021 - 2033 (USD Million)

6.14. Others

6.14.1. Others Market, 2021 - 2033 (USD Million)

CHAPTER 7. ROUTE OF ADMINISTRATION BUSINESS ANALYSIS

- 7.1. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Movement Analysis
- 7.2. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Segment Dashboard
- 7.3. Route of Administration Movement & Market Share Analysis, 2024 & 2033
- 7.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Route of Administration
- 7.5. Oral
 - 7.5.1. Oral Market, 2021 - 2033 (USD Million)
- 7.6. Parenteral
 - 7.6.1. Parenteral Market, 2021 - 2033 (USD Million)
- 7.7. Transdermal
 - 7.7.1. Transdermal Market, 2021 - 2033 (USD Million)
- 7.8. Nasal
 - 7.8.1. Nasal Market, 2021 - 2033 (USD Million)
- 7.9. Other Route of Administration
 - 7.9.1. Other Route of Administration Market, 2021 - 2033 (USD Million)

CHAPTER 8. DISTRIBUTION CHANNEL BUSINESS ANALYSIS

- 8.1. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Movement Analysis
- 8.2. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Segment Dashboard
- 8.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2033
- 8.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Distribution Channel
- 8.5. Offline Retail Pharmacies
 - 8.5.1. Offline Retail Pharmacies Market, 2021 - 2033 (USD Million)
 - 8.5.2. Chain Pharmacies
 - 8.5.2.1. Chain Pharmacies Market, 2021 - 2033 (USD Million)
 - 8.5.3. Specialty Retail Pharmacies
 - 8.5.3.1. Specialty Retail Pharmacies market, 2021 - 2033 (USD Million)
 - 8.5.4. Independent Community Pharmacies
 - 8.5.4.1. Specialty Market, 2021 - 2033 (USD Million)
- 8.6. Online Pharmacies / Telehealth
 - 8.6.1. Online Pharmacies / Telehealth Market, 2021 - 2033 (USD Million)
- 8.7. Others (Specialized Peptide Clinics)

8.7.1. Others (Specialized Peptide Clinics) Market, 2021 - 2033 (USD Million)

CHAPTER 9. COMPETITIVE LANDSCAPE

- 9.1. Company Categorization (Offline Pharmacies)
- 9.2. Company Categorization (Online Pharmacies)
- 9.3. Company Categorization (Specialized Hormone Clinics)
- 9.4. Participant's Overview
 - 9.4.1. Offline Pharmacies
 - 9.4.2. Online Pharmacies
 - 9.4.3. Specialized Hormone Clinics
- 9.5. Company Market Position Analysis
- 9.6. Strategy Mapping
 - 9.6.1. Regional Expansion
 - 9.6.2. Mergers & Acquisitions
 - 9.6.3. Others
- 9.7. Company Profiles/Listing
- 9.8. Offline Pharmacies
 - 9.8.1. CVS Health
 - 9.8.1.1. Overview
 - 9.8.1.2. Financial performance
 - 9.8.1.3. Product benchmarking
 - 9.8.1.4. Strategic initiatives
 - 9.8.2. Walgreens Boots Alliance, Inc.
 - 9.8.2.1. Overview
 - 9.8.2.2. Financial performance
 - 9.8.2.3. Product benchmarking
 - 9.8.2.4. Strategic initiatives
 - 9.8.3. Walmart Pharmacy
 - 9.8.3.1. Overview
 - 9.8.3.2. Financial performance
 - 9.8.3.3. Product benchmarking
 - 9.8.3.4. Strategic initiatives
 - 9.8.4. Rite Aid Corp
 - 9.8.4.1. Overview
 - 9.8.4.2. Financial performance
 - 9.8.4.3. Product benchmarking
 - 9.8.4.4. Strategic initiatives
 - 9.8.5. The Kroger Co.

- 9.8.5.1. Overview
- 9.8.5.2. Financial performance
- 9.8.5.3. Product benchmarking
- 9.8.5.4. Strategic initiatives
- 9.8.6. Albertsons
 - 9.8.6.1. Overview
 - 9.8.6.2. Financial performance
 - 9.8.6.3. Product benchmarking
 - 9.8.6.4. Strategic initiatives
- 9.8.7. Publix
 - 9.8.7.1. Overview
 - 9.8.7.2. Financial performance
 - 9.8.7.3. Product benchmarking
 - 9.8.7.4. Strategic initiatives
- 9.8.8. Costco Wholesale Corporation
 - 9.8.8.1. Overview
 - 9.8.8.2. Financial performance
 - 9.8.8.3. Product benchmarking
 - 9.8.8.4. Strategic initiatives
- 9.8.9. Meijer, Inc.
 - 9.8.9.1. Overview
 - 9.8.9.2. Financial performance
 - 9.8.9.3. Product benchmarking
 - 9.8.9.4. Strategic initiatives
- 9.9. Online Pharmacies
 - 9.9.1. Hims & Hers Health, Inc
 - 9.9.1.1. Overview
 - 9.9.1.2. Financial performance
 - 9.9.1.3. Product benchmarking
 - 9.9.1.4. Strategic initiatives
 - 9.9.2. Ro (Roman Health Ventures Inc.)
 - 9.9.2.1. Overview
 - 9.9.2.2. Financial performance
 - 9.9.2.3. Product benchmarking
 - 9.9.2.4. Strategic initiatives
 - 9.9.3. Lemonaid Health, Inc.
 - 9.9.3.1. Overview
 - 9.9.3.2. Financial performance
 - 9.9.3.3. Product benchmarking

- 9.9.3.4. Strategic initiatives
- 9.9.4. Mark Cuban Cost Plus Drug Company, PBC
 - 9.9.4.1. Overview
 - 9.9.4.2. Financial performance
 - 9.9.4.3. Product benchmarking
 - 9.9.4.4. Strategic initiatives
- 9.9.5. Amazon.com, Inc.
 - 9.9.5.1. Overview
 - 9.9.5.2. Financial performance
 - 9.9.5.3. Product benchmarking
 - 9.9.5.4. Strategic initiatives
- 9.9.6. Blink Health Administration LLC, Inc.
 - 9.9.6.1. Overview
 - 9.9.6.2. Financial performance
 - 9.9.6.3. Product benchmarking
 - 9.9.6.4. Strategic initiatives
- 9.9.7. GoodRx, Inc
 - 9.9.7.1. Overview
 - 9.9.7.2. Financial performance
 - 9.9.7.3. Product benchmarking
 - 9.9.7.4. Strategic initiatives
- 9.9.8. Honeybee Health Inc.
 - 9.9.8.1. Overview
 - 9.9.8.2. Financial performance
 - 9.9.8.3. Product benchmarking
 - 9.9.8.4. Strategic initiatives
- 9.9.9. TruePill (acquired by LetsGetChecked in October 2024)
 - 9.9.9.1. Overview
 - 9.9.9.2. Financial performance
 - 9.9.9.3. Product benchmarking
 - 9.9.9.4. Strategic initiatives
- 9.9.10. AgelessRx
 - 9.9.10.1. Overview
 - 9.9.10.2. Financial performance
 - 9.9.10.3. Product benchmarking
 - 9.9.10.4. Strategic initiatives
- 9.10. Specialized Hormone Clinics
 - 9.10.1. Defy Medical
 - 9.10.1.1. Overview

- 9.10.1.2. Financial performance
- 9.10.1.3. Product benchmarking
- 9.10.1.4. Strategic initiatives
- 9.10.2. Renew Vitality
 - 9.10.2.1. Overview
 - 9.10.2.2. Financial performance
 - 9.10.2.3. Product benchmarking
 - 9.10.2.4. Strategic initiatives
- 9.10.3. Victory Men's Health
 - 9.10.3.1. Overview
 - 9.10.3.2. Financial performance
 - 9.10.3.3. Product benchmarking
 - 9.10.3.4. Strategic initiatives
- 9.10.4. Hone Health
 - 9.10.4.1. Overview
 - 9.10.4.2. Financial performance
 - 9.10.4.3. Product benchmarking
 - 9.10.4.4. Strategic initiatives
- 9.10.5. Joi & Blokes
 - 9.10.5.1. Overview
 - 9.10.5.2. Financial performance
 - 9.10.5.3. Product benchmarking
 - 9.10.5.4. Strategic initiatives
- 9.10.6. Ways2Well
 - 9.10.6.1. Overview
 - 9.10.6.2. Financial performance
 - 9.10.6.3. Product benchmarking
 - 9.10.6.4. Strategic initiatives
- 9.10.7. 4Ever Young Anti-aging Solutions
 - 9.10.7.1. Overview
 - 9.10.7.2. Financial performance
 - 9.10.7.3. Product benchmarking
 - 9.10.7.4. Strategic initiatives
- 9.10.8. T CLINICS USA
 - 9.10.8.1. Overview
 - 9.10.8.2. Financial performance
 - 9.10.8.3. Product benchmarking
 - 9.10.8.4. Strategic initiatives

List Of Tables

LIST OF TABLES

Table 1 List of secondary sources

Table 2 List of abbreviations

Table 3 Market size & forecasts and trend analysis for the therapeutics type segment, 2021 - 2033 (USD Million)

Table 4 Market size & forecasts and trend analysis for the indication segment, 2021 - 2033 (USD Million)

Table 5 Market size & forecasts and trend analysis for the route of administration segment, 2021 - 2033 (USD Million)

Table 6 Market size & forecasts and trend analysis for the distribution channel segment, 2021 - 2033 (USD Million)

Table 7 Market size & forecasts and trend analysis for the offline retail pharmacies type segment, 2021 - 2033 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value chain-based sizing & forecasting
- Fig. 7 Market formulation & validation
- Fig. 8 Market snapshot
- Fig. 9 Indication segment snapshot
- Fig. 10 Route of administration & therapeutics type segment snapshot
- Fig. 11 Distribution channel segment snapshot
- Fig. 12 Competitive landscape
- Fig. 13 U.S. pharmacy market value, 2024 (USD Billion)
- Fig. 14 U.S. peptide therapeutics (retail side) market dynamics
- Fig. 15 U.S. peptide therapeutics (retail side) market: Porter's five forces analysis
- Fig. 16 U.S. peptide therapeutics (retail side) market: PESTLE analysis
- Fig. 17 U.S. peptide therapeutics (retail side) market therapeutics type outlook: Segment dashboard
- Fig. 18 U.S. peptide therapeutics (retail side) market: Therapeutics type movement & market share analysis, 2024 & 2033
- Fig. 19 Innovative (branded) peptides market, 2021 - 2033 (USD Billion)
- Fig. 20 Generic peptides market, 2021 - 2033 (USD Billion)
- Fig. 21 Biosimilar peptides market, 2021 - 2033 (USD Billion)
- Fig. 22 U.S. peptide therapeutics (retail side) market indication outlook: Segment dashboard
- Fig. 23 U.S. peptide therapeutics (retail side) market: Indication movement & market share analysis, 2024 & 2033
- Fig. 24 Type 2 diabetes market, 2021 - 2033 (USD Billion)
- Fig. 25 Obesity/weight management market, 2021 - 2033 (USD Billion)
- Fig. 26 Prostate cancer market, 2021 - 2033 (USD Billion)
- Fig. 27 Breast cancer (hormone-sensitive) market, 2021 - 2033 (USD Billion)
- Fig. 28 Endometriosis market, 2021 - 2033 (USD Billion)
- Fig. 29 Growth hormone deficiency market, 2021 - 2033 (USD Billion)
- Fig. 30 Acromegaly market, 2021 - 2033 (USD Billion)
- Fig. 31 Osteoporosis market, 2021 - 2033 (USD Billion)

Fig. 32 Neuroendocrine tumors market, 2021 - 2033 (USD Billion)

Fig. 33 Others market, 2021 - 2033 (USD Billion)

Fig. 34 U.S. peptide therapeutics (retail side) market route of administration outlook:
Segment dashboard

Fig. 35 U.S. peptide therapeutics (retail side) market: Route of administration movement
& market share analysis, 2024 & 2033

Fig. 36 Oral market, 2021 - 2033 (USD Billion)

Fig. 37 Parenteral market, 2021 - 2033 (USD Billion)

Fig. 38 Transdermal market, 2021 - 2033 (USD Billion)

Fig. 39 Nasal market, 2021 - 2033 (USD Billion)

Fig. 40 Others market, 2021 - 2033 (USD Billion)

Fig. 41 U.S. peptide therapeutics (retail side) market distribution channel outlook:
Segment dashboard

Fig. 42 U.S. peptide therapeutics (retail side) market: Distribution channel movement &
market share analysis, 2024 & 2033

Fig. 43 Offline retail pharmacies market, 2021 - 2033 (USD Billion)

Fig. 44 Chain pharmacies market, 2021 - 2033 (USD Billion)

Fig. 45 Independent community pharmacies market, 2021 - 2033 (USD Billion)

Fig. 46 Specialty retail pharmacies market, 2021 - 2033 (USD Billion)

Fig. 47 Online pharmacies market, 2021 - 2033 (USD Billion)

Fig. 48 Others (specialized peptide clinics) market, 2021 - 2033 (USD Billion)

Fig. 49 Company categorization (Offline Pharmacies)

Fig. 50 Company categorization (Online Pharmacy)

Fig. 51 Company categorization (Specialized Clinics)

Fig. 52 Company market position analysis

Fig. 53 Company market position analysis

Fig. 54 Company market position analysis

Fig. 55 Strategic framework

I would like to order

Product name: U.S. Peptide Therapeutics (Retail Side) Market Size, Share & Trends Analysis Report By Peptide Type, By Indication, By Route of Administration, By Therapeutics Type, By Distribution Channel, And Segment Forecasts, 2025 - 2033

Product link: <https://marketpublishers.com/r/U117542447E1EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U117542447E1EN.html>